Quidel Corporation (QDEL)

Healthcare Medical Devices

16.80 $

+1.2% vs. previous close

Closing price · As of: 31. Jul 2026

Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Quidel Corporation.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Risk & Weakness

RS Weakness (≤10) Stage 4 (Downtrend) Stan Weinstein: Stage 4 Stan Weinstein: Stage 4B- Weakness Cluster

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap

1.2$B

Shares Outstanding

68Mio.

Float

91.1%

Beta

0.7

Performance

Perf. 1M

39.50%

Perf. 3M

23.30%

Perf. 6M

-36.90%

YTD Performance (%)

-58.20%

52-Week-High Distance

-62.0%

Perf. 1Y

-55.84%

Perf. 3Y

-85.90%

Perf. 5Y

-89.38%

Valuation

P/E

–

Forward P/E

7.2

PEG

2.1

P/B

–

P/S

0.4

EV/EBITDA

21.3

Price/FCF

–

Profitability

Gross Margin

45.2%

EBIT Margin

–

Net Margin

-45.6%

Return on Equity

-50.0%

Return on Assets

0.5%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

–

Altman Z″

2.43

Piotroski

3 out of 9

Growth

Sales Growth Last Quarter

-10.50%

EPS Growth Last Quarter

-77.10%

Sales Growth (Year)

-1.89%

Forward Sales Growth

3.45%

Forward EPS Growth

29.30%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

3 out of 9

Fundamental Rating

D (31 out of 100)

Altman Z″

2.43

AI Rating

–

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Analysts & Price Target

Current Price 16.80 $

Price Target (average) 18.88 $

The price target sits 12.4% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

6. Aug 2026 · after the close · Q2 2026

Expected Earnings per Share: -0.04 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

From To Indexed

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	-2.65	-2,652.40	708	-4.70	-25.20	64	17
2025: Q1	-0.19	–	693	-2.60	-1.80	66	76
2025: Q2	-3.77	–	614	-3.60	-41.60	-47	-40
2025: Q3	-10.78	–	700	-3.70	-104.70	-46	-95
2025: Q4	-1.93	–	724	2.20	-18.10	132	87
2026: Q1	-1.35	–	620	-10.50	-14.80	-33	-27

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

QuidelOrtho Corporation bietet Diagnostiklösungen an. Das Unternehmen ist in den Geschäftsbereichen Labs, Transfusion Medicine, Point of Care und Molecular Diagnostics tätig.

CEO Insider Trades (12 Mo.)	buying own stock
Employees	6,500
Headquarters	San Diego, CA
Website	quidelortho.com
IPO Date	1. Feb 1991

Management

Management
Name	Title	Birth Year
Brian J. Blaser	President, CEO & Director	1965
Joseph M. Busky C.P.A.	Chief Financial Officer	1968
Philip D. McLellan	Chief Operations Officer	1970
Jonathan P. Siegrist Ph.D.	Executive VP of Research & Development and CTO	1982
Juliet C. Cunningham	Vice President of Investor Relations	–
Nathaniel B. Sisitsky Esq.	Chief Legal Officer & Corporate Secretary	1974
Lisa S. Hayes	Vice President of Global Marketing & Corporate Communications	–
Bryan M. Hanson	Executive VP of Global Portfolio Management and Marketing	1980
Erich Wolff	Executive Vice President of Strategy & Corporate Development	–
Ronald Lee Bowman	Chief Human Resources Officer	1979

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.